linjc16/ctgov huggingface dataset:
Effect of Non Invasive Ventilation on Lung Volumes Determined by Electrical Impedance Tomography

Study Overview
=================
Brief Summary
-----------------
Effect of Non Invasive Ventilation on end-expiratory lung volumes determined by electrical impedance tomography

Detailed Description
-----------------
Prospective clinical study in ICU with patients requiring non invasive ventilation (NIV) comparing lung volumes determined by electrical impedance tomography before, during and after NIV. Duration of NIV is 30 minutes.

Official Title
-----------------
Effect of Non Invasive Ventilation on Lung Volumes Determined by Electrical Impedance Tomography

Conditions
-----------------
- Critical Care, Non Invasive Ventilation, Electrical Impedance Tomography, End Expiratory Lung Volume, End Expiratory Lung Impedance

Intervention / Treatment
-----------------
* Other: non invasive ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult ICU patients requiring non invasive ventilation Consent of patients or family Arterial line Exclusion Criteria: Tracheotomized patients Dressings in the thoracic area

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non invasive ventilation (NIV)<br> | Other: non invasive ventilation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| - End-expiratory lung volume (EELV) determined by electrical impedance tomography before, during and after NIV |  | at day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anterior, medio-anterior, medio-posterior and posterior EELV |  | at day 1 | 
| Ventilatory frequency |  | at day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
- Critical Care, Non invasive ventilation, Electrical impedance tomography, End expiratory lung volume, End expiratory lung impedance
Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications

Study Overview
=================
Brief Summary
-----------------
The study objective is to collect mid-term clinical outcome in a group of patients implanted with permanent pacemaker (PM) according to real-life clinical practice in a multicenter and international environment.

Detailed Description
-----------------
The principal objective of the OPTI-MIND study is to collect data on two-year all-cause mortality in a general population implanted with a PM according to current clinical practice. Additionally, the study aims to stratify the outcome by both known patient-related risk factors and by physiologic pacing mode setting (a specifically defined PM programming). Stratification will be done for pre-specified classes of patients on the basis of their primary rhythm disease.

Official Title
-----------------
Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications

Conditions
-----------------
Bradyarrhythmia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients implanted with a current Boston Scientific pacemaker (all ALTRUA models) or any future commercially available Boston Scientific PM families according to international and local guidelines for pacemaker implantation; Patients who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational centre; Patients whose age is 18 years or above, or of legal age to give informed consent specific to state and national law. Exclusion Criteria: Unable to be followed up by the participating centres for a period of two years; Current device implanted for more than 15 days; Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion); Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the patient is participating in a mandatory governmental registry or extensions/amendments of the current protocol. Each instance should be brought to the attention of the sponsor to determine eligibility.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pacemaker<br>Patients currently implanted with permanent Pacemaker according to guidelines | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Two-year All-cause Mortality |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiovascular, Pacemaker, Mortality, Physiologic pacing
The Relationship Among rSO2, MAP, et al by Near-Infrared Spectroscopy in Endovascular Neurosurgery

Study Overview
=================
Brief Summary
-----------------
record,describe and discuss the relationship among rSO2, MAP,CAM value, vital organ disfunction and the outcome of patients after operation by Near-Infrared Spectroscopy in Endovascular Neurosurgery

Detailed Description
-----------------
record,describe and discuss the relationship among rSO2, MAP,CAM value, vital organ disfunction and the outcome of patients after operation using Near-Infrared Spectroscopy in Endovascular Neurosurgery meanwhile detect the Brain oxygen supply and function monitoring using noninvasive Near-Infrared Spectroscopy in Endovascular Neurosurgery.

Official Title
-----------------
The Relationship Among rSO2, MAP,CAM Value, Vital Organ Disfunction and the Outcome of Patients After Operation by Near-Infrared Spectroscopy in Endovascular Neurosurgery

Conditions
-----------------
Near-Infrared Spectroscopy in Endovascular Neurosurgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiology (ASA) class I Ⅲ, ranging in age from 18 to 80 years Exclusion Criteria: ASA>Ⅳ Non-cooperators Morbid obesity (BMI>35kg/m2) Preoperative hyperresponsiveness airway and gastro-esophageal reflux The existence of the state or a diagnosis of dementia, delirium, depression, cognitive dysfunction before surgery were also excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| there is relationship between rSO2 and MAP during neurosurgery |  | 2 month | 
| there is relatinship between rSO2 and CAM values |  | 2 month | 
| vital organ disfunction related to rSO2 and bad outcome of the patients |  | 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Near-Infrared Spectroscopy
MASIMO Radical 7 and Laboratory Measurement

Study Overview
=================
Brief Summary
-----------------
Present study aimed to evaluate the accuracy of Masimo Radical 7 to monitor hemoglobin concentrations through compared with laboratory measurement during major hepatic surgery, and to determine the source of discordance between two methods.

Conditions
-----------------
Major Hepatic Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients American Society of Anesthesiologists Physical Status Ⅰor Ⅱ scheduled for potentially hemorrhagic major hepatic resection under general anesthesia requiring an arterial line Exclusion Criteria: coagulopathy hemoglobinopathy cardiac dysrhythmias arrhythmia intracardiac shunt heart valve diseases tinea unguium arterio puncture failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemoglobin measurement using the Masimo device |  | 0.5h after skin incision | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Hemoglobin measurement using the Masimo device |  | 1h and 3h after skin incision |
The Effect of Kinesio Taping on Ankle Proprioception

Study Overview
=================
Brief Summary
-----------------
This study examines the effect of kinesiology tape on proprioception and postural control in subjects with sub-acute and chronic ankle sprains/strain.

Detailed Description
-----------------
The a priori hypothesis of this study is that proprioception (knee repositioning error) and balance (sway velocity and center of pressure) will improve significantly after intervention (Kinesiotape) in participants with a history of acute or chronic ankle sprains/strains.

Official Title
-----------------
The Effect of Kinesio Taping on Ankle Proprioception

Conditions
-----------------
Sprains and Strains

Intervention / Treatment
-----------------
* Other: KinesioTape


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Logan student, staff, or faculty Between the ages of 20 and 65 Previous history of ankle instability/sprains A score of 6 out of 10 questions answered yes on the Functional Ankle Instability form will qualify the candidate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group 1<br>An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved | Other: KinesioTape<br>* An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Joint Position sense testing and postural control (sway velocity center of pressure) |  | Day 1, Day 2 and Day 3 of Study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS |  | Day 1, Day 2 and Day 3 of Study |
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Study Overview
=================
Brief Summary
-----------------
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.

Official Title
-----------------
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Conditions
-----------------
Anxiety Disorders

Intervention / Treatment
-----------------
* Drug: XBD173


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Current doctor's diagnosis of generalized anxiety disorder In need of psychiatric treatment Willingness to complete all aspects of the study Exclusion Criteria: Current doctor's diagnosis of major depression History of schizophrenia or schizoaffective disorders Drug dependence within 2 months prior to study start For detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website: www.novartisclinicaltrials.com

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: XBD173|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean reduction in anxiety from baseline to week 6 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The difference on day 4 in effect between placebo and the individual doses of XBD173 on reduction in anxiety and depression |  |  | 
| Pharmacokinetic assessments at baseline |  |  | 
| Pharmacogenetic assessments at baseline |  |  | 
| Pharmacogenomic and proteomic assessments at baseline |  |  | 
| Metabonomic assessments at visits 4, 7 and 10 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GAD, Anxiety, XBD173, Generalized Anxiety Disorder
Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

Study Overview
=================
Brief Summary
-----------------
This study hopes to evaluate whether the combination of Gemzar plus Alimta will have any beneficial effects for patients with recurrent platinum-sensitive or platinum-resistant ovarian or peritoneal cancer. Treatments are weekly for two weeks, with the 3rd week off and will be repeated every 21 days. Side effects and the overall safety of the treatment will also be monitored and evaluated. In addition, a Quality of Life questionnaire is part of this study to help measure patient perceived benefits or drawbacks to this treatment regimen.

Conditions
-----------------
Ovarian Cancer, Peritoneal Cancer

Intervention / Treatment
-----------------
* Drug: Gemzar and Alimta


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must have disease that can be measured. Patients must meet criteria for either platinum-resistant or platinum-sensitive ovarian or peritoneal cancer. Patients may only have had one prior platinum-based chemotherapy regimen. Patients must be willing and able to stop all aspirin and NSAID medications immediately before and for a time after each treatment cycle (approx. 5-8 days) Patients must have normal kidney function. Exclusion Criteria: Patients may not have a Low Malignant Potential or Borderline Ovarian Tumor. Patients may not have received pelvic or abdominal radiotherapy. Patients must not have evidence of or received treatment for another cancer within the last 5 years. Patients must not have been diagnosed with a heart attack in the last 6 months. Patients who are unwilling or unable to take folic acid tablets, vitamin B12 injections or dexamethasone tablets.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gemzar and Alimta|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recurrent ovarian cancer, platinum-resistant, platinum-sensitive, folate receptor antagonist
Outcomes and Patient Satisfaction After Colpocleisis for Pelvic Organ Prolapse

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the long-term success rate of the colpocleisis procedure and its effect on quality of life in women who have this surgery. We want to see if women who have this surgery have problems with recurrent pelvic organ prolapse, urinary incontinence, or bowel problems after the surgery. We also want to see how the surgery affects women's sexuality.

Official Title
-----------------
Outcomes and Patient Satisfaction After Colpocleisis for Pelvic Organ Prolapse

Conditions
-----------------
Pelvic Organ Prolapse

Intervention / Treatment
-----------------
* Other: Questionnaires, Physical Examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women who underwent either total colpectomy with colpocleisis or partial colpectomy with LeFort-type colpocleisis performed by the Urogynecology service between 1/2000 and 12/2007 at Strong Memorial Hospital Exclusion Criteria: women who are not undergone colpocleisis or colpectomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Physical examination, questionnaires, retrospective chart review | Other: Questionnaires, Physical Examination<br>* Questionnaires, Physical Examination<br>|
| 2<br>Questionnaires, retrospective chart review | Other: Questionnaires, Physical Examination<br>* Questionnaires, Physical Examination<br>|
| 3<br>Retrospective chart review | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaires |  | Post-operative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physical Examination |  | Post-operative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colpocleisis
Plasma Citrulline: A Marker for Monitoring & Quantifying Radiation-Induced Small Bowel Toxicity

Study Overview
=================
Brief Summary
-----------------
Small bowel irradiation results in epithelial cell loss and consequently impairs function and metabolism. A metabolic end product of small bowel enterocytes is plasma citrulline. The investigators evaluate the correlation between plasma citrulline level, dose-volume histogram of small bowel, and small bowel toxicity grade by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE ver.4.0) to investigate whether citrulline can be used as a biomarker for quantifying radiation-induced epithelial cell loss.

Conditions
-----------------
Diarrhea, Anorexia, Dyspepsia

Intervention / Treatment
-----------------
* Biological: Plasma citrulline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed cancer patients Appropriate liver, renal, and bone marrow function for radiotherapy Willing to provide informed written consent At least 20 years old Exclusion Criteria: prior abdominopelvic radiation therapy or chemotherapy or abdominal surgery Any contraindication to radiotherapy (i.e. Severe connective tissue disorder, etc.) Prior or simultaneous history of other malignancy On medication for small bowel disease or CTCAE 4.0 Grade 1 or higher toxicity before radiation Any treatment delay more than 1 week during radiotherapy No radiotherapy due to any other reason except small bowel toxicity

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Plasma citrulline<br> | Biological: Plasma citrulline<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serial changes in plasma citrulline level baseline, on 3rd week during, on the day of completion of radiotherapy, and 3 months post-radiotherapy. |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation coefficient between plasma citrulline and dose-volume histogram of small bowel. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Radiation-induced small bowel toxicity, Plasma citrulline